Recent Finacing
Recent Raise
JW Therapeutics is a Shanghai-based clinical-stage biopharmaceutical company developing CD19-directed CAR-T therapy JWCAR029 for relapsed/refractory B‑cell malignancies, with a validated clinical GMP facility and CFDA IND acceptance.
